635 High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective
β Scribed by S.N. Cullen; C. Rust; K. Fleming; U. Beuers; R.W. Chapman
- Book ID
- 117374911
- Publisher
- Elsevier Science
- Year
- 2006
- Tongue
- English
- Weight
- 248 KB
- Volume
- 44
- Category
- Article
- ISSN
- 0168-8278
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Previous controlled trials are inconclusive regarding the efficacy of ursodeoxycholic acid (UDCA) for treating primary sclerosing cholangitis (PSC). One hundred fifty adult patients with PSC were enrolled in a long-term, randomized, double-blind controlled trial of highdose UDCA (28-30 mg/kg/day) ve
Ursodeoxycholic acid (UDCA) has beneficial effects in cholestatic liver diseases. In primary sclerosing cholangitis (PSC), there is evidence that high doses (Ψ20 mg/kg) of UDCA may be more effective than average doses. Biliary enrichment of UDCA at such high doses may represent the decisive factor f